Company

SK Biopharmaceuticals Co. Ltd

Headquarters: Seongnam-si, South Korea

CEO: Mr. Jeong Woo Cho Ph.D.

KRX: 326030 -1.45%

Market Cap

₩6.187 Trillion

KRW as of July 1, 2024

US$4.47 Billion

Market Cap History

SK Biopharmaceuticals Co. Ltd market capitalization over time

Evolution of SK Biopharmaceuticals Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of SK Biopharmaceuticals Co. Ltd

Detailed Description

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

SK Biopharmaceuticals Co. Ltd has the following listings and related stock indices.


Stock: KRX: 326030 wb_incandescent

Details

Headquarters:

221, Pangyoyeok-ro

Bundang-gu

Seongnam-si, 13494

South Korea

Phone: 82 31 8093 0114

Fax: 82 31 8093 0000